Monograph Details

Gastrointestinal Tract > Hyperacidity, GERD, and ulcers
ZANTAC INJECTION PREMIXED
Manufacturer
GlaxoSmithKline Pharmaceuticals
Legal Classification
Rx
Pharmacological Class
H2 blocker.
Generic Name
Ranitidine (as HCl) 1mg/mL in sodium chloride 0.45%; IV infusion; preservative-free.
Also
ZANTAC
ZANTAC EFFERDOSE
ZANTAC INJECTION
ZANTAC SYRUP
Indications
Hospitalized patients with pathological hypersecretory conditions, intractable duodenal ulcer. Short-term alternative to oral therapy.
Children
<1month: not recommended. ≥1month–16yrs: Treatment of duodenal ulcer: 2–4mg/kg per day in divided doses every 6–8hrs; max 50mg every 6–8hrs.
Adults
For slow IV drip only. >16yrs: Intermittent infusion: 50mg every 6–8hrs (infuse over 15–20min); usual max 400mg/day. Continuous IV infusion, or for Zollinger-Ellison: see literature. Renal impairment (CrCl<50mL/min): 50mg every 18–24hrs or more often if needed (intermittent only). Coincide a dose for end of hemodialysis.
Precautions
History of acute porphyria: not recommended. Renal impairment: reduce dose. Hepatic dysfunction. Discontinue if hepatic disorders occur. Monitor SGPT if on high-dose IV therapy for ≥5 days. Pregnancy (Cat.B). Nursing mothers.
Interactions
May increase triazolam, midazolam, glipizide, procainamide levels. May decrease ketoconazole, atazanavir, delaviridine, gefitnib levels. Monitor anticoagulants. May cause false (+) urine protein test with Multistix.
Adverse Reactions
Headache, GI disturbances, jaundice, hepatitis, rash; rare: CNS disturbances, arrhythmias, blurred vision, arthralgia, myalgia, inj site reactions, blood dyscrasias, anaphylaxis, angioneurotic edema, acute interstitial nephritis, bradycardia with rapid administration (IV); increased risk of pneumonia (see literature).
How Supplied
Tabs 150mg—60, 180, 500
300mg—30
EFFERdose tabs—60
Syrup—pt
Inj single dose 2mL—10
Multidose 6mL—1
Premixed 50mL—24
Additional Resources
Related Prescribing Note